L3Harris Technologies Inc vs 10X Genomics Inc — how do they compare? L3Harris Technologies Inc trades at $288.12 (market cap $53.26B), while 10X Genomics Inc trades at $57.21 (market cap $7.61B). The key difference: L3Harris Technologies Inc is far larger — about 7× 10X Genomics Inc's market cap, and L3Harris Technologies Inc pays a 1.75% dividend while 10X Genomics Inc pays none. Which is the better fit depends on your goals.
| LHX | TXG | |
|---|---|---|
Market Cap | $53.26B | $7.61B |
Sector | Industrials | Health |
52-Week High | $378.48 | $58.57 |
52-Week Low | $270.21 | $11.34 |
Enterprise Value | $63.71B | $7.14B |
Dividend Yield | 1.75% | — |
Signals from Pluang's Aura AI — not financial advice
LHX trades at $285.18, down 1.57% today, with strong fundamental performance including three consecutive quarterly EPS beats and record $42 billion backlog. The company shows improving profitability with net margin expanding to 8.11% in 2026 projections. Recent defense contract wins and successful missile tests highlight operational momentum, though technical indicators show bearish pressure with price below key resistance levels.
LHX presents a compelling investment case with strong defense sector positioning, consistent earnings outperformance, and 72.7% analyst buy ratings targeting $319.33. Key risks include defense budget volatility and execution challenges in scaling production. The stock offers 12% upside to consensus target with dividend yield support, though near-term technical weakness requires monitoring.
TXG (10x Genomics) trades at $56.95, down 2.77% on the day. The stock exhibits bullish technical signals with strong moving averages, though RSI levels suggest overbought conditions. Fundamentally, the company shows improving trends with Q2 2026 earnings beating estimates and a narrowing net loss margin from -41.23% in 2023 to -12.18% in 2026. Recent news highlights collaborations with Cleveland Clinic and acquisition of Proteintech Genomics, expanding multiomics capabilities.
Outlook: Growth potential exists through market expansion and innovation, but risks include persistent unprofitability and high valuation multiples. Analyst sentiment is mixed with a $46 consensus target below current price, indicating caution despite recent operational improvements.
Trailing returns across standard periods
Latest headlines on both assets
L3Harris Technologies was created in 2019 from the merger of L3 Technologies and Harris, two defense contractors that provide products for the command, control, communications, computers, intelligence, surveillance, and reconnaissance (C4ISR) market. The firm also has smaller operations serving the civil government, particularly the Federal Aviation Administration's communication infrastructure, and produces various avionics for defense and commercial aviation.
Read more on LHX →10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →